CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 533 enrolled
Drug / intervention
Blood sampling for MR-proADM & CT-proET-1other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03651635
NCT03651635N/ACompleted
CompareCT.gov

To Assess and Validate the Use of MR-proADM and the CT-proET-1/MR-proADM Ratio as Prognostic Markers During the First 7 Days of ICU Treat-ment

University of Zurich·observational·Posted Aug 29, 2018·Updated Jun 2, 2021

In Brief

An observational study evaluating Blood sampling for MR-proADM & CT-proET-1 for Acute Phase Biomarkers and Medical ICU Admitted Patients. Completed, enrolled 533 participants across 1 site.

Detailed Summary

This pilot-study will be a prospective, single-centre, observational study including 100 critically ill patients consecutively admitted to the medical intensive care unit (ICU) of the University hospital of Zurich, Switzerland, to assess and validate the use of MR-proADM and the CT-proET1/MR-proADM-ratio as prognostic markers in critically ill patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Phase Biomarkers, Medical ICU Admitted Patients
CountriesSwitzerland
CollaboratorsThermoFisher Scientific Brahms Biomarkers France

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartJan 8, 2018
Primary CompletionFeb 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago

Interventions

Blood sampling for MR-proADM & CT-proET-1other

Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM \& CT-proET-1